Influence of lipid-lowering therapy integrating traditional Chinese and Western medicinals on inflammatory response in rats with renal atherosclerotic hypertension

Zhou Wang,Jing Shen,Yang Liu,Tianjiao Wang,Yunpeng Qu,Zhifeng Qin,Chaohong Ji,Jing Zhang
DOI: https://doi.org/10.3969/j.issn.1674-4055.2019.04.11
2019-01-01
Abstract:Objective To investigate the influence of lipid-lowering therapy integrating traditional Chinese and Western medicinals on level of blood fat and inflammatory response in rats with renal atherosclerotic hypertension (RASH). Methods Male Wistar rats were given parallel acupuncture stenosis method and high fat diet for 8 weeks for establishing the model of hypertension of atherosclerotic renal artery stenosis (ARAS). The rats were treated with different therapies and divided into blank control group (T0 group), Xuezhikang Capsule group (T1 group), group with rosuvastatin in general dose (T2 group), group with rosuvastatin in general dose combined with Xuezhikang Capsule (T3 group) and group with rosuvastatin in half dose combined with Xuezhikang Capsule (T4 group). After medicine intervention for 6 weeks, the levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) were observed. The renal and aortic expressions of myeloperoxidas (MPO) and matrix metalloproteinase-9 (MMP-9) were detected by using immunohistochemistry technique. Results ①The levels of TC, TG and LDL-C decreased significantly, and HDL-C increased significantly in all medicated groups than those in T0 group (P<0.05). ②The results of renal immunohistochemistry technique showed that average optical density (AOD) of MPO decreased significantly in all medicated groups (P<0.05), which was more significantly in T3 group, and difference was not significant between T4 group and T3 group (P>0.05). MMP-9 decreased significantly in T3 group and T4 group (P<0.05) and the difference was no significant between T3 group and T4 group (P>0.05). ③The results of aortic immunohistochemistry technique showed that AOD of MPO decreased significantly in T2 group, T3 group and T4 group (P<0.05). AOD of MMP-9 decreased significantly in T3 group and T4 group (P<0.05) and the difference was no significant between T3 group and T4 group (P>0.05). Conclusion Xuezhikang Capsule combined with rosuvastatin can reduce the dose of statins, improve effectively blood fat, decrease inflammatory factor level, and protect endothelial cells in treatment of ARAS hypertension.
What problem does this paper attempt to address?